Filing identity and business context
Important entity mismatch: Although the request identifies Envoy Medical, Inc., the supplied Form 10-Q is for Anzu Special Acquisition Corp I, a blank-check company (SPAC). It reports the quarter and six months ended June 30, 2021; it does not report Envoy Medical’s operating results.
Anzu completed its IPO in March 2021 and raised additional funds through a partial over-allotment exercise in April. It was searching for a business combination, with a stated focus on businesses using transformative technologies for industrial applications. It had not begun operations and expected no operating revenue before completing a business combination.
Financial results and position
| Metric | Period / date | Reported amount |
|---|---|---|
| Net income (loss) | Three months ended June 30, 2021 | $371,144 |
| Net income (loss) | Six months ended June 30, 2021 | $(1,099,292) |
| Formation and operating costs | Three months / six months ended June 30, 2021 | $1,071,142 / $1,254,607 |
| Interest earned on trust funds | Three months / six months ended June 30, 2021 | $15,376 / $23,217 |
| Cash and cash equivalents outside trust | June 30, 2021 | $1,739,367 |
| Cash held in trust | June 30, 2021 | $425,023,217 |
| Total assets | June 30, 2021 | $427,829,210 |
| Total liabilities | June 30, 2021 | $41,160,393 |
| Working capital | June 30, 2021 | $2,135,356 |
| Net cash used in operating activities | Six months ended June 30, 2021 | $(1,654,299) |
| Net cash provided by financing activities | Six months ended June 30, 2021 | $428,368,666 |
The filing reports no operating revenue, so operating margins are not meaningful. Cash-flow investing use of $425.0 million primarily reflects funds placed in the trust account. The company reported no long-term debt or working-capital loan borrowings. Liabilities included $14.875 million of deferred underwriting fees payable upon completion of a business combination and $25.615 million of derivative warrant liabilities.
Changes versus prior comparable period
The filing provides no prior-year quarterly operating comparison. The company was formed in December 2020 and completed its IPO during 2021. Compared with December 31, 2020, June 30, 2021 assets rose from $119,992 to $427.8 million, primarily due to the IPO and trust funding. The company reported a Q2 profit following a six-month loss; the quarter’s results included a $1.427 million gain from a decline in warrant-liability fair value, while the six-month results included a $782,812 charge for offering costs allocated to warrants.
Outlook, risks, and unusual items
- Management said it believed available funds were sufficient to pursue a business combination by March 4, 2023, but noted that higher-than-expected search, due-diligence, or negotiation costs could leave it short of operating funds. Additional financing might be needed to complete a transaction or address substantial shareholder redemptions.
- If no business combination is completed by March 4, 2023, or an approved extension, the company must wind up and redeem public shares under the stated terms; warrants may expire worthless.
- Management said COVID-19 could adversely affect the company’s financial position, operations, or target search, but the effect was not readily determinable.
- Warrants were classified as liabilities and remeasured at fair value. Management identified a material weakness in internal control over financial reporting related to warrant accounting. Remediation had begun but was not complete as of June 30, 2021; disclosure controls were therefore deemed ineffective.
- The filing states that no material legal proceedings or material changes to previously disclosed risk factors were reported. No subsequent events requiring adjustment or disclosure were identified through August 17, 2021.
Most important facts to verify
- Confirm whether this Anzu SPAC filing, rather than an Envoy Medical filing, is the intended source.
- Verify the trust balance and restrictions: substantially all trust funds were reserved for a business combination or permitted redemptions, not ordinary operating expenses.
- Review warrant-liability valuation and the related control weakness, including whether remediation was completed in later filings.
- Track business-combination progress, financing needs, redemption exposure, and the March 4, 2023 deadline or any approved extension.
- Note that the filing contains inconsistent monthly administrative-fee figures: $40,521 in the financial-statement note and $40,251 in MD&A.